| Website | tenshatherapeutic... |
| Category | BioTech |
| tensha@hcven.com | |
| Employees |
| TOTAL | $15M |
| FUNDING TOTAL | $15M |
| Series A, 9/11 HealthCare Ventures | $15M |
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.
